TransCode Therapeutics (NASDAQ:RNAZ) Stock Falls 2.1% – Time to Sell?

TransCode Therapeutics Inc. (NASDAQ:RNAZ) shares dropped 2.1% on Tuesday. The stock traded as low as $1.65 and last traded at $1.67. 7,503 shares traded hands during trading, The stock had previously closed at $1.7055.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of TransCode Therapeutics in a report on Thursday, October 15th. One investment analyst has rated the stock with a Sell rating. Based on data from MarketBeat, TransCode Therapeutics has an average rating of “Sell”.

TransCode Therapeutics Stock Down 0.6%

The firm has a market cap of $29.29 million, a PE ratio of -0.03 and a beta of 1.25. The firm’s fifty day simple moving average is $1.89 and its two-hundred day simple moving average is $6.22.

TransCode Therapeutics (NASDAQ:RNAZ) last issued its earnings results on Friday, August 14th. The company reported ($7.17) earnings per share (EPS) for the quarter.

About TransCode Therapeutics

TransCode Therapeutics, Inc is a clinical-stage biotechnology company focused on developing RNA-based medicines for cancer. The company is working to address metastatic disease by using its proprietary TTX delivery platform to transport therapeutic agents to tumor sites.

TransCode’s lead product candidate is TTX-MC138, an investigational therapy designed to inhibit microRNA-10b, a molecular target associated with the development and spread of metastatic cancer. The company has evaluated the candidate in early-stage clinical studies and has investigated its potential across multiple solid-tumor indications.

In addition to therapeutic development, TransCode’s platform is intended to support tumor imaging and the delivery of other RNA payloads.